SCHEDULE 13G/A: Biotechnology Value Fund Boosts Immunic Stake to 9.99%

Biotechnology Value Fund and its affiliates reported a combined beneficial ownership of 9.99% in Immunic, Inc., including significant warrant holdings.

Summary

• Biotechnology Value Fund L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively hold a significant stake in Immunic, Inc.
• As of June 30, 2025, Mark N. Lampert, BVF Inc., and BVF Partners L.P. are deemed to beneficially own 9,785,178 shares, representing 9.99% of Immunic's outstanding common stock.
• BVF beneficially owned 6,268,162 shares, or approximately 6.4% of the outstanding shares.
• BVF2 beneficially owned 3,027,105 shares, or approximately 3.2% of the outstanding shares.
• Trading Fund OS beneficially owned 315,231 shares, representing less than 1% of the outstanding shares.
• The reporting persons hold Pre-Funded Warrants exercisable for an aggregate of 8,580,151 shares, which were unexercisable as of June 30, 2025, due to a 9.9% beneficial ownership blocker.
• They also hold New Pre-Funded Warrants exercisable for an aggregate of 13,335,000 shares, with only 2,132,206 shares exercisable as of June 30, 2025, due to a 9.99% beneficial ownership blocker.
• Additionally, Series A Warrants for 13,335,000 shares (exercisable at $0.75, expiring December 31, 2025) and Series B Warrants for 13,335,000 shares (exercisable at $0.75, expiring five years from issuance, with specific activation conditions) are held.
• Both Series A and Series B Warrants were unexercisable as of June 30, 2025, due to a 9.99% beneficial ownership blocker, but can be converted into equivalent pre-funded warrants if blocked.
• The percentages are calculated based on 95,817,536 shares outstanding as of May 14, 2025, plus 2,132,206 shares issuable from New Pre-Funded Warrants.

Sentiment

Score: 7

Explanation: The filing indicates a strong, sustained interest from a specialized biotechnology investment fund, holding a near-maximum passive stake. The various warrant types provide long-term optionality, suggesting a positive outlook on Immunic's future, despite the current beneficial ownership blockers.

Positives

• A significant institutional investor, Biotechnology Value Fund, maintains a substantial stake in Immunic, Inc., indicating continued interest and potential confidence in the company's long-term prospects.
• The holding of various warrants (Pre-Funded, New Pre-Funded, Series A, Series B) provides the investor with future flexibility to increase their ownership at predetermined prices, potentially at a discount to future market values.

Negatives

• The presence of beneficial ownership blockers (9.9% and 9.99%) on the warrants prevents immediate full exercise, limiting the investor's ability to convert all potential shares into voting stock at present.
• The Series A Warrants have an expiry date of December 31, 2025, introducing a time constraint for their exercise.

Risks

• The beneficial ownership blockers could limit the investor's influence or ability to fully capitalize on their warrant holdings if the share price increases significantly.
• The expiry of Series A Warrants by December 31, 2025, means that if market conditions are not favorable or blockers remain, the value of these warrants could diminish or be lost.
• The exercise of warrants, when permitted, could lead to dilution for existing shareholders, increasing the total number of outstanding shares.

Future Outlook

The reporting persons hold various warrants that provide future optionality to increase their stake in Immunic, Inc. The Series B Warrants are exercisable upon certain conditions, including a volume-weighted average price (VWAP) target of $1.25 or greater over five trading days, or by October 1, 2025, or prior to a Fundamental Transaction. The ability to convert Series A and B Warrants into pre-funded warrants if beneficial ownership blockers apply offers a mechanism to maintain exposure without exceeding ownership limits.

Industry Context

This filing indicates a significant, albeit passive, investment by a specialized biotechnology fund in Immunic, Inc., a company likely operating in the biotechnology sector. Such substantial institutional holdings are common in the biotech industry, where long-term investment in promising drug development or therapeutic platforms is typical. The use of warrants with beneficial ownership blockers is a common strategy for institutional investors to manage their exposure and regulatory compliance while maintaining upside potential.

Comparison to Industry Standards

• The beneficial ownership percentage of 9.99% is a common threshold for institutional investors to approach without triggering more stringent reporting requirements or being deemed an 'insider' with control intent, which aligns with standard practices in the investment community.
• The structure of pre-funded and traditional warrants with exercise price and expiry dates is a standard financing mechanism in the biotechnology sector, often used to raise capital while providing investors with flexibility and downside protection (via low exercise price pre-funded warrants) and upside potential (via higher exercise price warrants).

Stakeholder Impact

• Shareholders: The significant stake held by Biotechnology Value Fund could be viewed positively as a vote of confidence from an institutional investor. However, the future exercise of warrants could lead to dilution of existing shareholders' ownership percentages.
• Company Management: The presence of a large institutional investor often implies increased scrutiny and potential for engagement on strategic decisions, though the filing states the securities were not acquired for control purposes.

Next Steps

• The Series B Warrants will become exercisable upon the earlier of October 1, 2025, the achievement of a VWAP target of $1.25 or greater over five trading days, or immediately prior to a Fundamental Transaction.
• The Series A Warrants will expire on December 31, 2025, requiring a decision on their exercise or conversion to pre-funded warrants before that date.

Key Dates

Recommendation

The filing primarily discloses a significant institutional ownership stake and warrant holdings, rather than new operational or financial performance data. While a large institutional investment can be a positive signal, the information itself does not provide a basis for a 'buy' or 'sell' recommendation. The various warrants offer future optionality, but their impact on the stock price is contingent on future exercise and market conditions. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future developments and the company's operational performance.

Keywords

Immunic Inc, Biotechnology Value Fund, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Warrants, Pre-Funded Warrants, Series A Warrants, Series B Warrants, Institutional Investor, Shareholder, Equity Stake, Biotechnology